2001
Isoniazid Preventive Therapy, Hepatitis C Virus Infection, and Hepatotoxicity among Injection Drug Users Infected with Mycobacterium tuberculosis
Sadaphal P, Astemborski J, Graham N, Sheely L, Bonds M, Madison A, Vlahov D, Thomas D, Sterling T. Isoniazid Preventive Therapy, Hepatitis C Virus Infection, and Hepatotoxicity among Injection Drug Users Infected with Mycobacterium tuberculosis. Clinical Infectious Diseases 2001, 33: 1687-1691. PMID: 11641824, PMCID: PMC2650436, DOI: 10.1086/323896.Peer-Reviewed Original ResearchConceptsHepatitis C virusInjection drug usersTuberculosis infectionValue elevationDrug usersCurrent injection drug useLatent Mycobacterium tuberculosis infectionHepatitis C virus infectionHepatitis B surface antigenLow HCV prevalenceC virus infectionIsoniazid preventive therapyInjection drug useM. tuberculosis infectionMycobacterium tuberculosis infectionHIV-1 infectionHuman immunodeficiency virusB surface antigenConcurrent alcohol useDrug discontinuationHCV prevalencePreventive therapyImmunodeficiency virusProspective studyTransaminase values
1990
Coinfection with tuberculosis and HIV-1 in male prison inmates.
Salive M, Vlahov D, Brewer T. Coinfection with tuberculosis and HIV-1 in male prison inmates. Public Health Reports 1990, 105: 307-10. PMID: 2113691, PMCID: PMC1580008.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultEpidemiologic MethodsHumansIsoniazidMaleMarylandPrisonersTuberculin TestTuberculosis, PulmonaryConceptsHIV-1HIV-1 antibody testingHuman immunodeficiency virus type 1Latent HIV-1 infectionImmunodeficiency virus type 1HIV-1 infectionVirus type 1Case-control designAnergy testingTB infectionAntibody testingMantoux testingElevated riskSignificant associationPast exposureTuberculosisType 1InfectionState prison systemMale prison inmatesAssociationPrison inmatesMale inmatesIntake samplesAdmission